The expression of ZBTB4 is downregulated in colon cancer, gastric cancer, retinoblastoma, Ewing sarcoma, breast cancer and prostate cancer, suggesting that ZBTB4 may have the potential to inhibit tumor development [7–13]. Here, ZBTB4 is linked to prostate carcinoma.